

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 November 2005 (10.11.2005)

PCT

(10) International Publication Number
WO 2005/104845 A1

- (51) International Patent Classification⁷: **A01N 37/20**, 37/12, 25/10, A61L 29/16, 29/14, 29/08
- (21) International Application Number: PCT/DK2005/000293
- (22) International Filing Date: 29 April 2005 (29.04.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PA 2004 00678 30 April 2004 (30.04.2004) DK
- (71) Applicant (for all designated States except US): **COLO-PLAST A/S** [DK/DK]; Holtedam 1, DK-3050 Humlebaek (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SAMUELSEN, Peter** [DK/DK]; Bukkeballevvej 18, DK-2960 Rungsted Kyst (DK). **KRISTIANSEN, Soeren** [DK/DK]; Toppen 20, DK-3390 Hundested (DK).
- (74) Common Representative: **NIELSEN, Leila**; COLO-PLAST A/S, Patent Department, Holtedam 1, DK-3050 Humlebaek (DK).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A HYDROPHILIC COATING OF A WATER-SWELLABLE HYDROPHILIC MATRIX AND AN ANTI-MICROBIAL POLYMER

(57) Abstract: The present invention relates to a hydrophilic coating of a water-swelling hydrophilic matrix having incorporated therein an anti-microbial polymer, said anti-microbial polymer carrying pendant groups providing the anti-microbial effect, said pendant groups being selected from primary amino groups, secondary amino groups, tertiary amino groups, quaternary ammonium groups, imino groups, and phosphonium groups.



WO 2005/104845 A1

A HYDROPHILIC COATING OF A WATER-SWELLABLE HYDROPHILIC MATRIX AND AN ANTI-MICROBIAL POLYMER

FIELD OF THE INVENTION

The present invention relates to a hydrophilic coating of a water-swelling hydrophilic matrix having incorporated therein an anti-microbial polymer. The present invention also relates to objects coated with such hydrophilic coatings, in particular medical devices.

BACKGROUND OF THE INVENTION

WO 02/17725 (D1) and WO 02/28927 (D2) disclose anti-microbial oligomers as well as polymer formulations comprising such oligomers combined with water-insoluble polymers. The oligomers and polymer formulations are used as coatings, varnishes and paints on a wide range of products, e.g. products within the field of medicine, e.g. coatings on contact lenses, catheters, etc.

WO 00/69264 (D3), WO 00/69925 (D4), WO 00/69933 (D5), and WO 00/69935 (D6) disclose anti-microbial polymers for producing anti-microbial polymer surfaces. The polymers are used as coatings on, or are grafted onto, a wide range of products, e.g. products within the field of medicine, e.g. coatings on contact lenses, catheters, etc.

BRIEF DESCRIPTION OF THE INVENTION

D1-D6 individually represent close prior art. The underlying problem to be solved in view of the prior art is to provide an anti-microbial effect to an object, where the effect is uniform over a predetermined period of time and not solely dependent on direct contact between the microbe and the surface of the object.

None of the references D1-D6 anticipate the incorporation of an anti-microbial polymer (or oligomer) into a water-swelling hydrophilic matrix. On the contrary, D1-D2 both suggest that the water-soluble oligomer may be used alone, i.e. the oligomer may be washed away from the surface of the object fairly rapidly, or that the oligomer may be combined with a water-insoluble polymer. In the latter case, the oligomer needs to be leached out of a water-insoluble polymer. Leaching out will become slower over time due to the formation of a leaching layer, i.e. the anti-microbial effect will be non-uniform. D3-D6 all suggest that the water-insoluble polymers or such polymer chains grafted to a surface are used to provide an

anti-microbial surface. Although such surfaces are more or less permanently anti-microbial, the effect requires direct contact between the microbes and the surface.

Thus, the present invention provides an elegant solution to the above problem, cf. claim 1.

The invention further provides an object, cf. claim 14.

5 DETAILED DESCRIPTION OF THE INVENTION

The hydrophilic coating

As mentioned above, the present invention relates to a hydrophilic coating of a water-swallowable hydrophilic matrix having incorporated therein an anti-microbial polymer, said anti-microbial polymer carrying pendant groups providing the anti-microbial effect, said pendant
10 groups being selected from primary amino groups, secondary amino groups, tertiary amino groups, quaternary ammonium groups, imino groups, and phosphonium groups.

Anti-microbial polymer

An important feature of the invention is the anti-microbial polymer which is incorporated in the hydrophilic matrix. The anti-microbial polymer is one which is carrying pendant groups
15 providing the anti-microbial effect, said pendant groups being selected from primary amino groups, secondary amino groups, tertiary amino groups, quaternary ammonium groups, imino groups, and phosphonium groups. It should – of course - be understood that two or more such polymer may be used in combination.

As used herein with respect to the presence of the anti-microbial polymer in the hydrophilic
20 coating, the term "incorporated" means that the anti-microbial polymer may be covalently bonded to the hydrophilic matrix or it may not be covalently bonded to the hydrophilic matrix.

In a preferred embodiment, all or an essential part of the anti-microbial polymer present in the hydrophilic coating is not covalently bonded to the hydrophilic matrix.

25 In another embodiment, all or an essential part of the anti-microbial polymer present in the hydrophilic coating is covalently bonded to the hydrophilic matrix.

The anti-microbial polymer typically has a weight average molecular weight in the range of 2,000-500,000, such as 4,000-250,000 or 4,000-50,000 or 50,000-250,000.

5 Examples of polymers carrying primary amino groups (-NH₂) are those incorporating monomers selected from the group consisting of 1-amino-propen, methacrylic acid-2-aminoethylester-hydrochloride, acrylic acid-3-aminopropyl ester, aminopropylmethacrylamide, aminoethylvinyl ether, and 3-aminopropylvinyl ether.

10 Secondary amino groups may be of the type (-NHR¹) where R¹ is selected from the group consisting of C₁₋₆-alkyl, aryl, aryl-C₁₋₆-alkyl (such as benzyl), heteroaryl, and heteroaryl-C₁₋₆-alkyl (such as heteroaryl-methyl). Examples of polymers carrying secondary amino groups (-NHR¹) are those incorporating monomers selected from the group consisting of 1-(N-methyl)amino-propen, methacrylic acid-2-(N-methyl)aminoethylester-hydrochloride, acrylic acid-3-(N-methyl)aminopropyl ester, (N-methyl)aminopropylmethacrylamide, (N-methyl)aminoethylvinyl ether, and 3-(N-methyl)aminopropylvinyl ether.

15 Tertiary amino groups may be of the type (-N(R¹)₂) wherein each R¹ independently is selected as defined above. Examples of polymers carrying tertiary amino groups (-N(R¹)₂) are those incorporating monomers selected from the group consisting of 1-(N,N-dimethyl)amino-propen, methacrylic acid-2-(N,N-dimethyl)aminoethylester-hydrochloride, acrylic acid-3-(N,N-dimethyl)aminopropyl ester, (N,N-dimethyl)aminopropylmethacrylamide, (N,N-dimethyl)aminoethylvinyl ether, and 3-(N,N-dimethyl)aminopropylvinyl ether.

25 Quaternary ammonium groups may be of the type (-N⁺(R¹)₃) wherein each R¹ independently is selected as defined above. Examples of polymers carrying quaternary ammonium groups (-N⁺(R¹)₃) are those incorporating monomers corresponding to those defined above for tertiary amines. For this series, the counter-ion (the anion) to the ammonium group may any conventionally used counter-ion, or may be selected from anions which in themselves provides an anti-microbial effect.

30 Imino groups may be of the type (-N=C(R²)₂) wherein each R² independently is selected from hydrogen and the groups defined above for R¹. Examples of polymers carrying imino groups (-N=C(R²)₂) are those incorporating monomers corresponding to those defined above for primary amines condensed with aldehydes or ketones.

Phosphonium groups may be of the type (-P⁺(R³)₃) wherein R³ is independently selected from the groups defined for R¹ above. Examples of polymers carrying phosphonium groups (-

$P^+(R^3)_3$) are those incorporating monomers selected from the group consisting of trimethylphosphoniummethacrylate and trimethylphosphoniummethacrylate. In this series, the counter-ion to the phosphonium groups may be selected as defined above for the quaternary ammonium group.

- 5 In a preferred embodiment, the anti-microbial polymer includes units derived from monomers selected from the group consisting of methacrylic acid-2-tert-butylaminoethylester, methacrylic acid-2-diethylaminoethylester, methacrylic acid-2-dimethylaminoethylester, methacrylic acid-2-diethylaminomethylester, acrylic acid-2-tert.-butylaminoethylester, acrylic acid-3-dimethylaminopropylester, acrylic acid-2-diethylaminoethylester, acrylic acid-2-
- 10 dimethylaminoethylester, dimethylaminopropylmethacrylamide, diethylamino-propylmethacrylamide, acrylic acid-3-dimethylaminopropylamide, 2-methacryloyloxyethyltrimethylammonium methosulphate, methacrylic acid-2-diethylaminoethylester, 2-methacryloyloxyethyltrimethylammonium chloride, 3-methacryloylaminopropyltrimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride, 2-acryloyloxyethyl-4-
- 15 benzoylbenzylidimethylammonium bromide, 2-methacryloyloxyethyl-4-benzoylbenzylidimethylammonium bromide, allyltriphenylphosphonium bromide, allyltriphenylphosphonium chloride, 2-acrylamido-2-methyl-1-propanesulfonic acid, 2-diethylaminoethylvinylether and/or 3-aminopropylvinylether.

Other monomers may be used as the balance in such anti-microbial polymers. Examples

20 hereof are acrylic acid, methyl acrylate, methacrylic acid, methyl methacrylic acid, etc. The anti-microbial polymer may thus be selected from the group consisting of polymethacrylates and polyacrylates, carrying the above mentioned pendant groups.

More particular examples of anti-microbial polymers are those produced by polymerisation of one of several monomers as disclosed in patents DE 199 21 894 A1, DE 199 21 897 A1, DE

25 199 21 898 A1, DE 199 21 900 A1 and WO 02/17725 A1 or equivalent, and commercial products such as AMINA[®] T 100 (Degussa).

The anti-microbial polymer may be introduced to the hydrophilic matrices by different approaches but preferably through direct formulation into the final mixture of the matrix, as will be described in detail further below.

30 Water-swellaible hydrophilic matrix

The most fundamental constituent of the hydrophilic coating is the water-swellaible hydrophilic matrix which has incorporated therein the anti-microbial polymer.

In the present context, the term "water-swellaable" means that the dry polymer is able to absorb more than 30% of its weight in pure water. However, preferably the dry polymer shall be able to absorb at least 100% by weight in water.

. In the present context a disintegrating swellaable hydrophilic matrix means a matrix that will
5 be able to pick up water to the characteristics of being water swellaable before it starts to disintegrate i.e. its boundaries loose integrity.

Thus, in one embodiment, the weight ratio between the non-swollen and the instantly swollen (typically within 90 seconds) coating will be at least 1:1.3, e.g. at least 1:2.

In some further interesting embodiments, the ratio of the thickness of the hydrophilic coating
10 in water swollen form (H_{water}) to the thickness of the hydrophilic coating in dry form (h_{dry}) is at least 2:1, such as at least 3:1.

The matrix typically comprises at least one water-swellaable hydrophilic polymer which provides the water-swellaability. In most instances, the matrix comprises at least 50% by solids weight of hydrophilic water-swellaable polymers, such as at least 80% or 90% or more
15 by solids weight of water-swellaable hydrophilic polymers.

The term "hydrophilic" means in this context any organic or polymeric compound which is soluble in water in concentrations higher than 100 g/L.

Examples of water-swellaable hydrophilic polymers are those selected from polyvinyl pyrrolidone, polyvinyl alcohol, poly(meth)acrylic acid, poly(meth)acrylic amides, polyethylene
20 glycol, carboxymethylcellulose, cellulose acetate, cellulose acetate propionate, chitosan, polysaccharides; and homopolymers or copolymers of two or more of the monomers: N-vinylpyrrolidone, vinyl alcohol, (meth)acrylic acid, (meth)acrylic amides, (meth)acrylic esters (such as hydroxyethyl methacrylate), maleic anhydride, maleimide, methyl vinyl ether, alkyl vinyl ethers, and other unsaturated compounds. Furthermore, the hydrophilic water-
25 swellaable polymer may be any derivative or any blend of these homopolymers or copolymers.

Most preferably, the hydrophilic polymer of the coating is selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone and copolymers including polyvinylpyrrolidone, e.g. polyvinylpyrrolidone-vinyl acetate copolymers. When using the pure polyvinylpyrrolidone (poly(N-vinyl-2-pyrrolidone); PVP), various chain lengths may be selected each giving
30 various characteristics to the coating. Typically, such polyvinylpyrrolidone polymers have a number average molecular weight of above 100,000. As an example, PVP K-90 with a

molecular weight of 1,200,000 can be selected but other types of PVP with other molecular weights may also be used.

In one interesting embodiment, the matrix comprises at least 50% by solids weight of one or more hydrophilic polymers selected from the group consisting of polyethylene glycol,
5 polyvinylpyrrolidone and copolymers including polyvinylpyrrolidone.

It is generally preferred that the matrix consists of non-cross-linked polymers.

In particular, the matrix should be at least partly soluble in water.

One way of determining the water-solubility is to store an amount of the matrix at 20°C in 1 L of pure water under stirring which over 24 hours at 20 degree C still leaves a non-
10 dissolved residue. The solubility of the matrix is the amount dissolved in g/L per gram matrix material and determine the time at which the matrix has fully disintegrated. Preferably, the matrix will fully disintegrate upon storage for 24 hours at 20°C in 1 L of pure water per gram matrix.

The coating should of course not disintegrate immediately, thus the type of polymer, the
15 chain length, etc. should preferably be selected so that the hydrophilic matrix disintegrates sufficiently slowly, i.e. such that it has not fully disintegrated upon storage for 2 hours at 20°C in 1 L of pure water per gram matrix.

The coating of the matrix and anti-microbial polymer

In order to obtain an even release profile for the anti-microbial polymer and the matrix, the
20 matrix and the anti-microbial polymer preferably form a homogeneous water-swelling coating.

The present invention is particularly relevant for fairly thick coatings as those useful for medical devices, such as catheters, e.g. urinary catheters. Thus, in an interesting
25 embodiment, the thickness in dry form (h_{dry}) of the hydrophilic coating is at least 3 μm , such as 6 μm , e.g. 3-1500 μm , such as 6-500 μm .

*The object*Substrate

The hydrophilic coating is most often applied to a substrate so as to provide anti-microbial properties to an object. Such objects, e.g. medical devices and medical device elements, can be formed from a variety of types of basic materials, such as plastics, metals, glass, ceramics, etc. Typical examples of plastic materials for medical devices are polymers such as polyurethanes and copolymers thereof, or polyether block amides such as Pebax™ or other polymer materials including polyvinyl chloride, polyamide, silicone, styrene-ethylene/butylene-styrene block copolymers (SEBS), styrene-isoprene-styrene block copolymers (SIS), styrene-ethylene/propylene-styrene block copolymers (SEPS), ethylene-vinyl acetate copolymers (EVA), polyethylene (PE), metallocene-catalyzed polyethylene, and copolymers of ethylene and propylene or mixtures of such. For some of the combinations of substrate polymers and hydrophilic coatings (e.g. polyethylene as a substrate polymer and PVP as the hydrophilic polymer) a primer coat (e.g. a PVC or polyurethane solution) may advantageously be applied before application of the polymer solution. Still further the substrate may be moulds of metal, glass or equivalent. The substrate will inherently normally be hydrophobic. Currently very relevant materials for medical devices are polyurethanes and copolymers thereof.

Within the present context, the medical device has on at least a part of the surface thereof (i.e. on at least a part of the surface of the basic material) a hydrophilic coating as defined herein. In some embodiments, the hydrophilic coating is applied to the full (outer) surface of the substrate polymer, and in some other embodiments, only to a part of the surface. In the most relevant embodiments, the coating is applied to at least a part of the surface (preferably the whole surface) of a medical device that - upon proper use - comes into direct contact with body parts of the person for which the medical device is intended.

The substrate is preferably at least part of an object, e.g. a medical device. Thus, a further aspect of the present invention relates to an object comprising a substrate material and a coating covering at least a part of the surface of said substrate material, said coating being a hydrophilic coating as defined herein. As mentioned above, the substrate material is typically selected from the group consisting of plastics, metals, glass, and ceramics.

Preferably, the object is a medical device or a medical device element, preferably a medical device or medical device element selected from the group consisting of catheters, endoscopes, laryngoscopes, tubes for feeding, tubes for drainage, guide wires, condoms,

urisheaths, barrier coatings, stents and other implants, extra corporeal blood conduits, membranes, blood filters, devices for circulatory assistance, dressings for wound care, and ostomy bags. Currently most relevant medical devices or medical device elements are catheters and catheter elements.

5 *Preparation of the hydrophilic coating*

A hydrophilic coating defined herein may be prepared by one of the following general procedures.

Equilibration of existing hydrophilic matrix

10 One way of providing the hydrophilic coating of the invention is to dissolve the anti-microbial polymer in a water phase, and equilibrate an already existing hydrophilic matrix with this solution so as to allow the anti-microbial polymer to penetrate the hydrophilic matrix.

Thus, in one variant, the aqueous solution used to equilibrate the matrix may comprise:

15 10^{-5} -20 wt/vol% of the anti-microbial polymer,
0-10 wt/vol% of polyvinylpyrrolidone and/or of polyethylenglycol,
0-50 wt/vol% of one or more osmolality increasing agents, and
20-99.5 wt/vol% of solvent.

The aqueous solution should preferably have a pH in the range of 3.5-8.5.

Thus, an object with a hydrophilic coating according to the invention may be provided through a method comprising the steps of:

20 (I) providing a substrate polymer having the substrate surface,

(II) providing a polymer solution comprising one or more hydrophilic polymers,

(III) applying said polymer vehicle solution to said substrate,

(IV) optionally evaporating at least a part of the vehicle from said polymer solution present on said substrate polymer surface, and

(VI) adding a solution containing the anti-microbial polymer to the hydrophilic matrix.

An advantage of this method is that the step of allowing the anti-microbial to penetrate the hydrophilic matrix does not necessitate any changes in the procedure for establishing the hydrophilic matrix as such.

Preparation of matrix with anti-microbial polymer

In another variant, the anti-microbial polymer may be added to the polymer solution intended to produce the matrix on the medical device. In particular, the ingredients required for the formation of the matrix may be solubilized in water or any other aqueous mixture or organic solvent. The polymer solution may be based on water, or, preferably, ethanol or other alcohols, or mixture thereof. Currently preferred solvents include those selected from N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetone, 1,3-dioxolane and dimethyl formamide. However, any solvent can in principle be used for the vehicle. Other options may therefore include methylethylketon, diethylether, dioxan, hexan, heptan, benzol, toluol, chloroform, dichlormethan, tetrahydrofuran and acetonitril, 1,3-dioxolane and other ethers, acetone and other ketones, dimethylsulfoxide and other sulfoxides, dimethyl formamide and other amides, N-methyl-2-pyrrolidone and other lactams, glycols, glycol ethers, glycol esters, other esters, amines, heterocyclic compounds, alkylated urea derivatives, liquid nitriles, nitroalkanes, haloalkanes, haloarenes, trialkyl phosphates, dialkyl alkanephosphonates, and other commonly known organic solvents. The preferred solvents may either be used singly or in combination. Typically, the solvent(s) constitute(s) 50-95% by weight of the polymer solution. In practical, the choice of mixture may be selected on the basis of the substrate since specific organic solvents may be required for the partly solubilization of the substrate surface. For example in a preferred embodiment of the invention, the vehicle may comprise mixtures of water, ethanol or ethanol and N-methyl-2-pyrrolidone.

Thus, in one embodiment of the invention the polymer solution used to produce the matrix may comprise:

10⁻⁵-20 wt/vol% of the anti-microbial polymer,
0.2-50 wt/vol% of a hydrophilic polymer,
0-40 vol/vol% of one or more plastizers,
0-50 wt/vol% of one or more osmolality increasing agents, and
20-99.5 wt/vol% of solvent.

The polymer solution should preferably have a pH in the range of 3.5-8.5.

The preferred plasticizers are glycols i.e. glycerol, polyethylene glycols, polypropylene glycols or acetyl triethyl citrate, dimethyl sulfone, ethylene carbonate, glycerol diacetate, glycerol triacetate, hexamethylphosphoramide, isophorone, methyl salicylate, N-acetyl morpholine,
5 propylene carbonate, quinoline, sulfolane, triethyl citrate, and triethyl phosphate. Particular examples are acetyl triethyl citrate. The plasticizers may be used singly or in combination. The plasticizer(s) preferably constitute(s) 1-40% by weight of the polymer solution.

The volatile vehicle solution comprising the above ingredients can be applied to the substrate surface by conventionally techniques (dipping, spraying, incubation, rolling etc.) and may
10 subsequently be dried by evaporation of solvents. The matrix can then later be swollen with water or an aqueous solution prior to use in order to give low friction properties.

Thus, an object with a hydrophilic coating according to the invention may be provided through a method comprising the steps of:

- (I) providing a substrate polymer having the substrate surface,
- 15 (II) providing a polymer solution comprising one or more hydrophilic polymers and an anti-microbial polymer,
- (III) applying said polymer vehicle solution to said substrate, and
- (IV) optionally evaporating at least a part of the vehicle from said polymer solution present on said substrate polymer surface.

20

Step (I)

As mentioned above, the substrate may be the native surface of a medical device or another object, or may be surface treated so as to facilitate strong bonding of the hydrophilic matrix
25 to the substrate. The surface of the substrate may be the complete physical surface or a fraction thereof. For instance with many medical devices, it is only necessary to coat the part of the substrate polymer surface, which comes into direct contact with the surface of living

tissue when in use. Thus, the step of providing a substrate having the substrate surface will be evident for the person skilled in the art. In a special embodiment, the surface of the substrate can be in the form of a mould. After formation of the matrix, the matrix is removed from the mould and the mould may therefore not be an integrated part of the final medical device.

Step (II)

The choice of hydrophilic polymer and optionally monomers, vehicle including water, solvent(s) and plasticizer(s) and additives including the anti-microbial oligomer or polymer is described above. The solution may be prepared by mixing the components of the vehicle with the hydrophilic polymer in order to obtain the polymer solution. The mixing order is not particularly critical as long as a homogeneous (and possibly clear) solution is obtained. Thus, the step of actual preparation of the polymer solution may be evident for the person skilled in the art in view of the above directions with respect to choice of vehicle components.

Step (III)

Application of the polymer solution to said substrate surface is conducted following conventional methods such as bar coating, reverse roll coating, dip coating, spray coating, application by means of brushes, rollers, etc., as will be evident for the person skilled in the art. With due consideration of the production process, it is preferred that the application of the polymer to the substrate polymer surface is performed by dipping the medical device (or the relevant surface thereof) into the polymer solution when non-planar and using bar coating with or for planar species.

The polymer solution is applied to a substrate polymer surface in one or more steps, suitably in one single application step, such as in a one-dip process. It should however be understood that the substrate polymer may be primed in one or more preceding step and that such a preceding step may be applied in addition to a single application step (one-dip process).

Step (IV)

After application of the polymer solution to the substrate surface, any organic solvent is evaporated from the polymer solution present on said substrate polymer surface. The solvents may be removed by passive evaporation, by leading a stream of air over the surface of the substrate, or by applying a reduced pressure over the surface of the substrate.

Furthermore, it may be necessary or desirable to increase the temperature of the substrate or the air surrounding the substrate to speed up the evaporation process. Preferably, the evaporation process is facilitated by drying the substrate with the polymer solution at a temperature of between 25-100°C depending on the thermostability of the substrate and the polymer. Typically, the substrate (e.g. a medical device) is dried in an oven. When water constitutes the entire solvent system or a part of the solvent system, preferably no or only part of this is evaporated as a rehydration step is eliminated for instance in case of sheet hydrogels.

Combination

10 Alternatively, in a third embodiment both approaches may be combined; the anti-microbial polymer may present in the solution required to equilibrate the matrix and present in the polymer solution required for the production of the hydrophilic matrix.

Thus, an object with a hydrophilic coating according to the invention may be provided through a method comprising the steps of:

- 15 (I) providing a substrate polymer having the substrate surface,
- (II) providing a polymer solution comprising one or more hydrophilic polymers and an antimicrobial polymer
- (III) applying said polymer vehicle solution to said substrate,
- (IV) optionally evaporating at least a part of the vehicle from said polymer solution present
20 on said substrate polymer surface, and
- (VI) adding a solution containing the anti-microbial polymer to the hydrophilic matrix.

After-treatment

The hydrophilic coating may afterwards be dried or may be sizing and packed in a suitable form. For medical devices, the package is preferably sterilized subsequent to packing.

25 The hydrophilic matrix in form of a coating become highly lubricious when wet as the coating takes up a significant amount of water, which leaves a non-bonded layer of free water

molecules at the surface of the coating. The non-bonding character of the surface water is believed to cause the low friction of the wet coating. Hence, the coating when applied to a biomedical or other device will improve biocompatibility and patient compliance. However, for most applications there will be high demands to the internal and the bonding strength for the coating. Thus, in a preferred embodiment of the invention the coating on the medical device may be packed in an un-swollen - or dry - condition, and saturated with a solution preferentially water before use. The solution used to saturate the coating may be a part of the packing device and therefore provided by the manufacturer, or the solution may be added and provided by the end-user. Alternatively, the coating on the medical device may also be packed in a swollen state and the solution is therefore added by the manufacturer prior to the sterilization process.

EXAMPLES

Example 1

A hydrophilic coating on a catheter from PVC is produced from applying a first coating layer by immersion of the catheter into a mixture of 5.4 g of low viscosity nitrocellulose, 2.0 g dibutyl phthalate and 1.9 g polyvinylbutyral (PVB) in a mixed solvent comprising isopropanol, ethyl acetate, ethanol and acetone (6:25:18:1.5 vol/vol) adding up to 100 g. After drying in 5 minutes at 65°C and additional outer layer was applied in a second coating step by dipping in a solution of 6.6 g of polyvinylpyrrolidone (Plasdone K 90) and 0.5 g antimicrobial polymer (Amina T 100) in a solvent of ethanol and N-vinyl pyrrolidone (80:20 vol/vol) adding up to 100 g. The catheter was allowed to dry 24 hours at 65°C.

Example 2

A hydrophilic coating on a catheter form PVC is produced as of Example 1 with the addition of 1.5 g urea to the solution of the second coating step.

Example 3

A hydrophilic coating on a catheter form PVC is produced as of Example 1 with the addition of 2.5 g sodium chloride finely milled to the solution of the second coating step. The second coating step is performed under gentle stirring of coating media.

Example 4

6.0 g polyurethane (Desmodur L 2291, Bayer AG) composed by trimerized diisocyanate of biuret is dissolved in 94.0 g methylene chloride. A urinary polyurethane catheter is dipped in this solution for 30 seconds, whereafter the the catheter is dried at 65°C for one minute. In a
5 second coating step the catheter is dipped in a solution of 33 g polyvinylpyrrolidone (Plasdone K 90 (ISP)/ MW 90,000), 1.0 g Amina T 100 and 66 g methylene chloride. The catheter is allowed to dry at ambient temperature followed by a one hour drying at 80°C.

Example 5

A coating as of Example 4 to which in a third step an extra coating layer is applied. The third
10 step consists of a coating solution containing 20% by weight of sodium chloride, 5% of PVP (Plasdone K25/ MW 25.000) and 0.2 g Amina T 100 in same solvent. A 24 hours drying step concludes the processing of the catheter.

Example 6

A PVC tubing is dip coated in a polymer solution of 5.4 g low viscosity nitrocellulose, 2.0 g
15 dibutylphthalate, 1.5 g camphor in a solvent mixture of 36 ml toluene, 13.1 ml butylacetate, 5.9 ml isopropanol, 25.4 ml ethyl acetate, 18.1 ml ethylalcohol, and 1.5 ml acetone. The tube is dried for 5 minutes at 65°C. It is thereafter dipped in a hydrophilic polymer solution containing 6.6 g polyvinylpyrrolidone (Plasdone K 90), 0.6 g Amina T 100, 64 ml ethylalcohol, 24 ml ethyl acetate, 13 ml dimethylformamide and finally dried at 80°C for 24 hours.

CLAIMS

1. A hydrophilic coating of a water-swellaible hydrophilic matrix having incorporated therein an anti-microbial polymer, said anti-microbial polymer carrying pendant groups providing the anti-microbial effect, said pendant groups being selected from primary amino groups,
5 secondary amino groups, tertiary amino groups, quaternary ammonium groups, imino groups, and phosphonium groups.
2. The hydrophilic coating according to claim 1, wherein the anti-microbial polymer has a weight average molecular weight in the range of 2,000-500,000.
3. The hydrophilic coating according to any one of the preceding claims, wherein the anti-
10 microbial polymer includes units derived from monomers selected from the group consisting of methacrylic acid-2-tert-butylaminoethylester, methacrylic acid-2-diethylaminoethylester, methacrylic acid-2-dimethylaminoethylester, methacrylic acid-2-diethylaminomethylester, acrylic acid-2-tert.-butylaminoethylester, acrylic acid-3-dimethylaminopropylester, acrylic acid-2-diethylaminoethylester, acrylic acid-2-dimethylaminoethylester,
15 dimethylaminopropylmethacrylamide, diethylamino-propylmethacrylamide, acrylic acid-3-dimethylaminopropylamide, 2-methacryloyloxyethyltrimethylammonium methosulphate, methacrylic acid-2-diethylaminoethylester, 2-methacryloyloxyethyltrimethylammonium chloride, 3-methacryloylaminopropyltrimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride, 2-acryloyloxyethyl-4-benzoyldimethyl-
20 ammonium bromide, 2-acryloyloxyethyl-4-benzoylbenzyldimethylammonium bromide, 2-methacryloyloxyethyl-4-benzoyldimethylammonium bromide, 2-methacryloyloxyethyl-4-benzoylbenzyldimethylammonium bromide, allyltriphenylphosphonium bromide, allyltriphenylphosphonium chloride, 2-acrylamido-2-methyl-1-propanesulfonic acid, 2-diethylaminoethylvinylether and 3-aminopropylvinylether.
- 25 4. The hydrophilic coating according to any one of the preceding claims, wherein the anti-microbial polymer is selected from the group consisting of polymethacrylates and polyacrylates.
5. The hydrophilic coating according to any one of the preceding claims, wherein the weight ratio between the non-swollen and the instantly swollen coating will be at least 1:1.3.
- 30 6. The hydrophilic coating according to any one of the preceding claims, wherein the water-swellaible hydrophilic matrix comprises at least one hydrophilic polymer selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol, polyacrylic acid, polymethacrylic

acid, polyacrylic amides, polymethacrylamide, polyethylene glycol, carboxymethylcellulose, cellulose acetate, cellulose acetate propionate, chitosan, any other polysaccharides, and grafts or copolymers of any of these polymers such as copolymers with maleic anhydride, succinic anhydride or the corresponding acids.

- 5 7. The hydrophilic coating according to claim 6, wherein the matrix comprises at least 50% by polymer solids weight of one or more hydrophilic polymers selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone and copolymers including polyvinylpyrrolidone.
8. The hydrophilic coating according to any one of the preceding claims, wherein the matrix
10 consists of non-cross-linked polymers.
9. The hydrophilic coating according to any one of the preceding claims, wherein the matrix is at least partly soluble in water.
10. The hydrophilic coating according to claim 9, wherein the matrix will fully disintegrate upon storage for 24 hours at 20°C in 1 L of pure water per gram matrix.
- 15 11. The hydrophilic coating according to any one of the preceding claims, wherein the matrix has not fully disintegrated upon storage for 2 hours at 20°C in 1 L of pure water per gram matrix.
12. The hydrophilic coating according to any one of the preceding claims, wherein the matrix and the anti-microbial polymer form a homogeneous water-swellaable coating.
- 20 13. The hydrophilic coating according to any one of the preceding claim, wherein the thickness in dry form (h_{dry}) of the hydrophilic coating is at least 3 μm .
14. An object comprising a substrate material and a coating covering at least a part of the surface of said substrate material, said coating being a hydrophilic coating as defined in any one of the claims 1-13.
- 25 15. The object according to claim 14, wherein the substrate material is selected from the group consisting of plastics, metals, glass, and ceramics.
16. The object according to any one of the claims 14-15, which is a medical device or a medical device element.

17. The object according to claim 16, wherein the medical device or medical device element is selected from the group consisting of catheters, endoscopes, laryngoscopes, tubes for feeding, tubes for drainage, guide wires, condoms, urisheaths, barrier coatings, stents and other implants, extra corporeal blood conduits, membranes, blood filters, devices for circulatory assistance, dressings for wound care, and ostomy bags.

18. The object according to claim 17, wherein medical device or medical device element is a catheter or catheter element.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK2005/000293

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A01N37/20 A01N37/12 A01N25/10 A61L29/16 A61L29/14 A61L29/08				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A01N A61L				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 98/58988 A (COLOPLAST AS ; MADSEN NIELS JOERGEN (DK)) 30 December 1998 (1998-12-30) page 1, line 4 - line 20 page 5, line 16 - page 6, line 3 page 6, line 26 - page 8, line 5; examples 7,8	1-7,9-18		
Y	----- WO 94/16747 A (RODSTEN CARSTEN BOB ; COLOPLAST AS (DK)) 4 August 1994 (1994-08-04) the whole document ----- -/--	1-18		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">22 September 2005</div>	Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">06/10/2005</div>			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center; font-weight: bold;">Muellners, W</div>			

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/DK2005/000293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/28927 A (KOSSMANN BEATE ; CREAVIS TECH & INNOVATION GMBH (DE); OTTERSBACK PETER) 11 April 2002 (2002-04-11) cited in the application page 1, line 3 - line 4 page 1, line 11 - line 24 page 3, line 16 - page 4, line 26 page 6, line 28 - page 7, line 10 page 8, line 26 - page 9, line 3; claims 1,17,18,21	1-18
A	EP 0 217 771 A (ASTRA MEDITEC AB) 8 April 1987 (1987-04-08) page 2, line 36 - line 49 page 3, line 2 - line 11	1-18
A	US 5 001 009 A (WHITBOURNE RICHARD J) 19 March 1991 (1991-03-19) column 1, line 51 - line 68 column 3, line 23 - column 4, line 27; example 5	1-18
A	US 6 110 483 A (ZHANG XIANPING ET AL) 29 August 2000 (2000-08-29) column 1, line 65 - column 2, line 37 column 5, line 40 - line 52 column 8, line 26 - line 36 column 8, line 59 - column 10, line 25; claim 22; example 1	1-18
A	US 4 769 013 A (CREASY WALTER S ET AL) 6 September 1988 (1988-09-06) column 1, line 50 - line 63 column 2, line 6 - line 48; example 3	1-18
A	EP 0 761 243 A (UNION CARBIDE CHEM PLASTIC) 12 March 1997 (1997-03-12) page 2, line 10 - line 19 page 1, line 41 - page 3, line 2 page 3, line 30 - page 4, line 15 page 4, line 48 - line 52 page 5, line 5 - line 26; examples 4,5,161-9	1-18
A	US 4 589 873 A (GRAPER JANE ET AL) 20 May 1986 (1986-05-20) column 1, line 7 - line 13 column 2, line 4 - column 4, line 53 column 5, line 18 - line 30; example 3	1,6-11, 13-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DK2005/000293

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9858988	A	30-12-1998	AT 227754 T	15-11-2002
			AU 8011698 A	04-01-1999
			DE 69809420 D1	19-12-2002
			DE 69809420 T2	17-07-2003
			EP 0991701 A1	12-04-2000
			ES 2185173 T3	16-04-2003
WO 9416747	A	04-08-1994	AT 270907 T	15-07-2004
			AU 660873 B2	06-07-1995
			AU 5880694 A	15-08-1994
			DE 69433893 D1	19-08-2004
			DE 69433893 T2	28-07-2005
			DK 7193 A	22-07-1994
			EP 0639990 A1	01-03-1995
			ES 2223045 T3	16-02-2005
WO 0228927	A	11-04-2002	AU 1387202 A	15-04-2002
			DE 10048613 A1	11-04-2002
EP 0217771	A	08-04-1987	AU 591703 B2	14-12-1989
			AU 6246486 A	02-04-1987
			CA 1292649 C	03-12-1991
			DE 3682742 D1	16-01-1992
			DE 217771 T1	15-10-1987
			DK 169552 B1	28-11-1994
			ES 2002009 A6	01-07-1988
			FI 863922 A	31-03-1987
			HK 12995 A	03-02-1995
			IE 58507 B1	06-10-1993
			JP 1960898 C	10-08-1995
			JP 6091898 B	16-11-1994
			JP 62082968 A	16-04-1987
NO 863872 A	31-03-1987			
US 4906237 A	06-03-1990			
US 5001009	A	19-03-1991	EP 0570370 A1	24-11-1993
			WO 9213718 A1	20-08-1992
US 6110483	A	29-08-2000	AU 8159898 A	04-01-1999
			CA 2293370 A1	30-12-1998
			CN 1261288 A	26-07-2000
			DE 69830590 D1	21-07-2005
			EP 1003571 A2	31-05-2000
			JP 2002506369 T	26-02-2002
WO 9858690 A2	30-12-1998			
US 4769013	A	06-09-1988	NONE	
EP 0761243	A	12-03-1997	CA 2185056 A1	09-03-1997
US 4589873	A	20-05-1986	NONE	